Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 11/20 | 0.62 |
| ▸ | AXL | P30530 | 5/20 | 0.58 |
| ▸ | KDR | P35968 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 4/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.48 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.48 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.46 |
| ▸ | FLT3 | P36888 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1471850 | 0.93 | MET (0.59) | METAXLKDRMEN1KMT2A | |
| SCHEMBL29251367 | 0.87 | MET (0.67) | METAXLKDRMEN1KMT2A | |
| SCHEMBL1472526 | 0.86 | AXL (0.54) | METAXLKDRMEN1KMT2A | |
| SCHEMBL1472307 | 0.86 | AXL (0.52) | METAXLKDRRIPK2RIPK1 | |
| SCHEMBL1472345 | 0.85 | AXL (0.53) | METAXLKDRRIPK2RIPK1 | |
| SCHEMBL1472350 | 0.85 | MET (0.59) | METAXLKDRRIPK2RIPK1 | |
| SCHEMBL14148079 | 0.84 | AXL (0.48) | METAXLKDRNTRK1 | |
| SCHEMBL4882739 | 0.84 | KDR (0.55) | METAXLKDR | |
| SCHEMBL29251647 | 0.83 | MET (0.86) | METAXLKDRMEN1KMT2A | |
| SCHEMBL29251384 | 0.83 | MET (0.62) | METAXLKDRMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2125780-B1 | SUBSTITUTED HETEROCYCLES AND METHODS OF USE | AMGEN INC (US) | 2012-08-29 | — | — | EP | disclosed |
| EP-2125780-B1 | SUBSTITUTED HETEROCYCLES AND METHODS OF USE | AMGEN INC (US) | 2012-08-29 | — | — | EP | disclosed |
| US-7915287-B2 | Use treating hepatocyte growth factor (HGF)-mediated diseases such as cancer; inhibitors of c-Met; e.g. 3-(3-fluoro-4-(7-methoxyquinolin-4-yloxy)phenylamino)-N-phenylpyrazine-2-carboxamide | AMGEN INC. (US) | 2011-03-29 | — | — | US | disclosed |
| US-7915287-B2 | Use treating hepatocyte growth factor (HGF)-mediated diseases such as cancer; inhibitors of c-Met; e.g. 3-(3-fluoro-4-(7-methoxyquinolin-4-yloxy)phenylamino)-N-phenylpyrazine-2-carboxamide | AMGEN INC. (US) | 2011-03-29 | — | — | US | disclosed |
| US-7915287-B2 | Use treating hepatocyte growth factor (HGF)-mediated diseases such as cancer; inhibitors of c-Met; e.g. 3-(3-fluoro-4-(7-methoxyquinolin-4-yloxy)phenylamino)-N-phenylpyrazine-2-carboxamide | AMGEN INC. (US) | 2011-03-29 | — | — | US | disclosed |
| EP-2125780-A1 | SUBSTITUTED HETEROCYCLES AND METHODS OF USE | Amgen Inc. (US) | 2009-12-02 | — | — | EP | disclosed |
| US-20080200464-A1 | Substituted heterocycles and methods of use | AMGEN INC. (US) | 2008-08-21 | — | — | US | disclosed |
| US-20080200464-A1 | Substituted heterocycles and methods of use | AMGEN INC. (US) | 2008-08-21 | — | — | US | disclosed |
| US-20080200464-A1 | Substituted heterocycles and methods of use | AMGEN INC. (US) | 2008-08-21 | — | — | US | disclosed |
| WO-2008079294-A1 | SUBSTITUTED HETEROCYCLES AND METHODS OF USE | AMGEN INC. (US) | 2008-07-03 | — | — | WO | disclosed |
| WO-2008079294-A1 | SUBSTITUTED HETEROCYCLES AND METHODS OF USE | AMGEN INC. (US) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200464-A1 | Substituted heterocycles and methods of use | HGF, HGFAC, MET | MET 3/4885AXL 578/4885KDR 231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.